Background: Hyperhidrosis is defined as excessive sweating which can be primary or secondary. Data about the prevalence of primary hyperhidrosis are scarce for northern Europe. Objective: Our aim was to investigate the prevalence of hyperhidrosis focusing on its primary form and describe the quality of life impairments for the affected individuals. Methods: Five thousand random individuals aged 18-60 years in Sweden were investigated. The individuals' addresses were obtained from Statens personadressregister, SPAR, which includes all persons who are registered as resident in Sweden. A validated questionnaire regarding hyperhidrosis including the Hyperhidrosis Disease Severity Scale (HDSS) and 36-item Short Form (SF-36) health survey was sent to each individual. The participants were asked to return the coded questionnaire within 1 week. Results: A total of 1,353 individuals (564 male, 747 female and 42 with unspecified gender) with a mean age of 43.1 ± 11.2 years responded. The prevalence of primary hyperhidrosis was 5.5%, and severe primary hyperhidrosis (HDSS 3-4 points) occurred in 1.4%. Secondary hyperhidrosis was observed in 14.8% of the participants. Our SF-36 results showed that secondary hyperhidrosis causes a significant (p < 0.001) impairment of both mental and physical abilities while primary hyperhidrosis impairs primarily the mental health (p < 0.001). Conclusion: Hyperhidrosis affects individuals in adolescence as a focal form while occurring as a generalised form with increasing age. Further, the prevalence of primary hyperhidrosis described in our study is comparable to other studies from the western hemisphere. While secondary, generalised hyperhidrosis impairs both physical and mental aspects of life, primary hyperhidrosis, with the exception of severe cases, mainly affects the mental health.

Keywords:
Hyperhidrosis, Prevalence, Survey, Quality of life
1.
Adar R, Kurchin A, Zweig A, Mozes M: Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 1977;186:34-41.
2.
Strutton DR, Kowalski JW, Glaser DA, Stang PE: US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004;51:241-248.
3.
Li X, Chen R, Tu Y-R, Lin M, Lai F-C, Li Y-P, Chen J-F, Ye J-G: Epidemiological survey of primary palmar hyperhidrosis in adolescents. Chin Med J 2007;120:2215-2217.
4.
Fujimoto T, Kawahara K, Yokozeki H: Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis. J Dermatol 2013;40:886-890.
5.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I: Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 2013;227:10-13.
6.
Iwase S, Ikeda T, Kitazawa H, Hakusui S, Sugenoya J, Mano T: Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis. J Auton Nerv Syst 1997;64:65-73.
7.
Ro KM, Cantor RM, Lange KL, Ahn SS: Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg 2002;35:382-386.
8.
Leachman SA, Kaspar RL, Fleckman P, Florell SR, Smith FJ, McLean WH, Lunny DP, Milstone LM, van Steensel MA, Munro CS, O'Toole EA, Celebi JT, Kansky A, Lane EB: Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 2005;10:3-17.
9.
Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A: Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010;163:1072-1076.
10.
Hornberger J, Grimes K, Naumann M, et al: Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol 2004;51:274-286.
11.
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, Smith KC, Storwick G; Canadian Hyperhidrosis Advisory Committee: A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg 2007;33:908-923.
12.
Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, et al: Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther 2003;25:298-308.
13.
Naumann MK, Hamm H, Lowe NJ; Botox Hyperhidrosis Clinical Study Group: Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002;147:1218-1226.
14.
Shayesteh A, Boman J, Janlert U, Brulin C, Nylander E: Primary hyperhidrosis: implications on symptoms, daily life, health and alcohol consumption when treated with botulinum toxin. J Dermatol 2016;43:928-933.
15.
Cina CS, Clase CM: The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 1999;8:693-698.
16.
Swartling C, Naver H, Lindberg M: Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001;8:247-252.
17.
McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD: The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
18.
Hund M, Kinkelin I, Naumann M, Hamm H: Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 2002;138:539-541.
19.
Lear W, Kessler E, Solish N, Glaser DA: An epidemiological study of hyperhidrosis. Dermatol Surg 2007;33:69-75.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.